Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19061532 | EXTRACTION OF ANTIMETHANOGENIC COMPOUNDS | February 2025 | June 2025 | Allow | 4 | 1 | 1 | Yes | No |
| 19003326 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SKIN DISEASES AND CONDITIONS INCLUDING ECZEMA | December 2024 | May 2025 | Allow | 4 | 0 | 1 | Yes | No |
| 18932631 | COMPOSITION FOR IMPROVING RESPIRATORY HEALTH OF COMPANION ANIMALS | October 2024 | January 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 18891931 | EXTRACTION OF ANTIMETHANOGENIC COMPOUNDS | September 2024 | January 2025 | Allow | 4 | 0 | 1 | Yes | No |
| 18889340 | COMPOSITION AND USE THEREOF FOR THE TREATMENT OF EQUINE GASTRIC ULCER SYNDROME | September 2024 | January 2025 | Allow | 4 | 0 | 1 | Yes | No |
| 18600907 | SOLUBILIZATE WITH CURCUMIN AND OPTIONALLY AT LEAST ONE OTHER ACTIVE SUBSTANCE | March 2024 | October 2024 | Allow | 7 | 0 | 0 | Yes | No |
| 18439503 | APPARATUSES AND SYSTEMS FOR PREPARING A MEAT PRODUCT | February 2024 | October 2024 | Allow | 8 | 1 | 2 | Yes | No |
| 18412174 | BIOLOGIC ENHANCEMENT FORMULATION | January 2024 | September 2024 | Allow | 8 | 1 | 2 | Yes | No |
| 18395925 | METHODS AND COMPOSITIONS FOR TREATING MUSCULOSKELETAL DISEASES, TREATING INFLAMMATION, AND MANAGING SYMPTOMS OF MENOPAUSE | December 2023 | May 2025 | Allow | 17 | 1 | 1 | Yes | No |
| 18531157 | Parallel Cell Processing Method and Facility | December 2023 | June 2025 | Allow | 18 | 2 | 1 | Yes | No |
| 18506930 | Thin Film Cell Encapsulation Devices | November 2023 | June 2025 | Allow | 20 | 0 | 2 | Yes | No |
| 18493979 | MATERIALS AND METHODS FOR INHIBITING A VIRAL INFECTION, INCLUDING A CORONAVIRUS INFECTION | October 2023 | May 2025 | Allow | 19 | 1 | 1 | Yes | No |
| 18376832 | Carbon Capture by Algal Inoculation of Ocean Ice and/or Sea Ice | October 2023 | June 2025 | Allow | 20 | 0 | 1 | Yes | No |
| 18376827 | MATERIALS AND METHODS FOR ALGAL INOCULATION TO EFFECT DIRECT CAPTURE OF CARBON DIOXIDE FROM AIR | October 2023 | June 2025 | Allow | 20 | 0 | 1 | Yes | No |
| 18479701 | COMPOSITIONS AND METHODS FOR TREATMENT OF SKIN DISORDERS | October 2023 | June 2025 | Abandon | 20 | 0 | 1 | No | No |
| 18477298 | IMMUNOMODULATORY COMPOSITIONS COMPRISING MICROBIAL ENTITIES | September 2023 | May 2025 | Allow | 19 | 1 | 1 | Yes | No |
| 18468980 | Placental Tissue Compositions | September 2023 | May 2025 | Abandon | 20 | 0 | 1 | No | No |
| 18243568 | METHOD FOR GUT MUCOSA PREPARATION TO ENHANCE MICROBIAL ENGRAFTMENT | September 2023 | March 2025 | Allow | 19 | 1 | 3 | Yes | No |
| 18364153 | HUMAN AND NON-HUMAN ANIMAL USE OF MICROBIAL ANAPLEROTIC OIL | August 2023 | January 2025 | Allow | 18 | 0 | 1 | Yes | No |
| 18361067 | Method to Convert Insects or Worms into Nutrient Streams and Compositions Obtained Thereby | July 2023 | October 2024 | Allow | 15 | 0 | 1 | Yes | No |
| 18358465 | MUSCLE DERIVED CELLS FOR THE TREATMENT OF URINARY TRACT PATHOLOGIES AND METHODS OF MAKING AND USING THE SAME | July 2023 | April 2025 | Abandon | 20 | 0 | 1 | No | No |
| 18357888 | METHODS AND COMPOSITIONS OF BIOCONTROL OF PLANT PATHOGENS | July 2023 | February 2025 | Allow | 19 | 1 | 1 | Yes | No |
| 18352386 | THRAUSTOCHYTRIDS, FATTY ACID COMPOSITIONS, AND METHODS OF MAKING AND USES THEREOF | July 2023 | May 2025 | Allow | 22 | 1 | 1 | Yes | No |
| 18351286 | METHODS FOR TREATING POLYMICROBIAL INFECTIONS | July 2023 | July 2024 | Allow | 12 | 0 | 1 | Yes | No |
| 18351385 | METHODS FOR TREATING POLYMICROBIAL INFECTIONS | July 2023 | July 2024 | Allow | 13 | 0 | 0 | Yes | No |
| 18351018 | CORAL COMPOSITE EXTRACT, COMPOSITION INCLUDING THE SAME AND METHOD OF PRODUCING THE SAME | July 2023 | February 2024 | Allow | 7 | 0 | 0 | Yes | No |
| 18212059 | BIOPOLYMER COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF GASTRIC ULCERS | June 2023 | October 2024 | Allow | 16 | 2 | 1 | Yes | No |
| 18337884 | METHOD FOR TESTING DRUG RESPONSE OF CARDIOMYOCYTES | June 2023 | February 2025 | Abandon | 20 | 0 | 1 | No | No |
| 18210113 | GLUCOSYLATED STEVIOL GLYCOSIDE AS A FLAVOR MODIFIER | June 2023 | December 2024 | Allow | 18 | 1 | 1 | Yes | No |
| 18331085 | TERPENE-BASED COMPOSITIONS, METHODS OF PREPARATIONS AND USES THEREOF | June 2023 | February 2025 | Abandon | 21 | 0 | 1 | No | No |
| 18203306 | MATERNAL SUPPLEMENT | May 2023 | April 2024 | Allow | 10 | 0 | 1 | Yes | No |
| 18142392 | COMPOSITIONS AND METHODS FOR DIGESTIVE HEALTH IN AN ANIMAL | May 2023 | April 2024 | Allow | 12 | 1 | 1 | Yes | No |
| 18306316 | Probiotic Formulations for Improving Athletic Performance | April 2023 | February 2025 | Abandon | 22 | 1 | 1 | No | No |
| 18305361 | Highly Scalable and Practical Method for Immobilizing and Efficiently Culturing Algae for Various Applications | April 2023 | July 2023 | Allow | 3 | 0 | 1 | Yes | No |
| 18304264 | IMMUNOMODULATORY COMPOSITIONS COMPRISING MICROBIAL ENTITIES | April 2023 | August 2023 | Allow | 4 | 0 | 1 | Yes | No |
| 18296774 | COMPOSITION COMPRISING AN ALGAL PROTEOGLYCAN EXTRACT AND USE THEREOF | April 2023 | September 2024 | Allow | 17 | 3 | 1 | Yes | No |
| 18130118 | ORAL COMPOSITION COMPRISING LACTIC ACID BACTERIA FOR REGULATING IMMUNE RESPONSES AND METHODS RELATED THERETO | April 2023 | July 2024 | Allow | 16 | 0 | 1 | Yes | No |
| 18129335 | METHOD OF SYNERGETIC MINIMIZATION OF NEGATIVE IMPACT CAUSED BY FLIGHTS ON HUMAN HEALTH | March 2023 | February 2024 | Allow | 10 | 0 | 1 | Yes | No |
| 18186095 | BIOSENSORS FOR DETECTING AND/OR NEUTRALIZING BIOAVAILABLE URANIUM AND RELATED U-SENSITIVE GENETIC MOLECULAR COMPONENTS, GENE CASSETTES, VECTORS, GENETIC CIRCUITS, COMPOSITIONS, METHODS AND SYSTEMS | March 2023 | January 2025 | Allow | 22 | 1 | 2 | Yes | No |
| 18181495 | METHODS AND COMPOSITIONS FOR TREATING MUSCULOSKELETAL DISEASES, TREATING INFLAMMATION, AND MANAGING SYMPTOMS OF MENOPAUSE | March 2023 | November 2023 | Allow | 8 | 0 | 1 | Yes | No |
| 18178966 | CHOLESTEROL REDUCING COMPOSITIONS AND METHODS OF USE THEREOF | March 2023 | July 2024 | Allow | 16 | 1 | 1 | Yes | No |
| 18019979 | Compositions and Methods for Treating Viral Infection | February 2023 | October 2023 | Allow | 8 | 0 | 1 | Yes | No |
| 18162774 | Variable Diameter Bioreactors | February 2023 | October 2024 | Allow | 21 | 1 | 2 | Yes | No |
| 18160950 | COMPOSITIONS AND METHODS FOR TREATMENT OF SARS-COV-2 | January 2023 | March 2024 | Allow | 13 | 2 | 2 | Yes | No |
| 18146706 | NOVEL BIFIDOBACTERIUM BACTERIA AND COMPOSITION INCLUDING NOVEL BIFIDOBACTERIUM BACTERIA | December 2022 | August 2024 | Allow | 19 | 2 | 1 | Yes | No |
| 18079155 | NUTRITIONAL COMPOSITION | December 2022 | March 2024 | Allow | 15 | 1 | 1 | Yes | No |
| 18063267 | THERAPEUTIC USE OF ENGINEERED POSTBIOTICS COMPRISING BACTERIOCINS AND/OR ENDOLYSINS | December 2022 | July 2023 | Allow | 8 | 0 | 1 | Yes | No |
| 18063447 | Methods and reagents for treating diabetes | December 2022 | August 2024 | Abandon | 21 | 1 | 1 | No | No |
| 18074837 | PLATED HEPATOCYTES AND PREPARATION AND USES THEREOF | December 2022 | November 2024 | Allow | 23 | 2 | 2 | Yes | No |
| 17979346 | INDIGENOUS AND IMPROVED BACTERIALLY FERMENTED CBD, CBG AND RELATED CANNABINOID ORAL DOSAGE FORMS | November 2022 | February 2024 | Allow | 16 | 0 | 1 | Yes | No |
| 17967886 | COPPER CHELATION THERAPEUTICS | October 2022 | July 2024 | Allow | 21 | 0 | 2 | Yes | No |
| 17957524 | MINT MASK AND METHODS OF USE THEREOF | September 2022 | June 2024 | Abandon | 20 | 0 | 1 | No | No |
| 17915306 | PHARMACEUTICAL COMPOSITION COMPRISING NEW LACTOBACILLUS PLANTARUM KC3 STRAIN AND LEONURUS JAPONICUS EXTRACT AS ACTIVE INGREDIENTS FOR PREVENTING OR TREATING RESPIRATORY DISEASE AND USE THEREOF | September 2022 | April 2025 | Allow | 30 | 0 | 1 | Yes | No |
| 17945125 | Blood Plasma Product | September 2022 | December 2023 | Allow | 15 | 1 | 2 | Yes | No |
| 17899752 | FRUIT AND VEGETABLE POMACE COMPOSITION AND USE AS BLOOD GLUCOSE MODULATOR AND ANTI-DIABETIC AGENT | August 2022 | April 2024 | Allow | 19 | 1 | 1 | Yes | No |
| 17821134 | DEXTROMETHORPHAN AND GUAIFENESIN SYRUP FORMULATION OR SUSPENSION | August 2022 | October 2023 | Allow | 14 | 0 | 1 | Yes | No |
| 17821138 | DIPHENHYDRAMINE SYRUP FORMULATION OR SUSPENSION | August 2022 | October 2024 | Abandon | 26 | 1 | 1 | No | No |
| 17819050 | COMPOSITIONS COMPRISING PROPIONIBACTERIUM ACNES BACTERIOPHAGES FOR TREATING ACNE | August 2022 | November 2023 | Allow | 15 | 1 | 2 | Yes | No |
| 17818772 | HUMAN AND NON-HUMAN ANIMAL USE OF MICROBIAL ANAPLEROTIC OIL | August 2022 | June 2023 | Allow | 10 | 1 | 0 | Yes | No |
| 17818749 | COMPOSITIONS AND METHODS FOR TREATING SKIN | August 2022 | November 2023 | Allow | 15 | 1 | 0 | Yes | No |
| 17816515 | METHOD OF TRANSPORTING MESENCHYMAL STEM CELLS BY MEANS OF A TRANSPORTING SOLUTION AND A METHOD OF ADMINISTERING STEM CELLS TO WOUNDS | August 2022 | January 2024 | Allow | 18 | 1 | 1 | Yes | No |
| 17812873 | INHIBITION OF ENTERIC INFECTION THROUGH THE MODULATION OF MICROBIOTA | July 2022 | September 2023 | Allow | 14 | 0 | 1 | Yes | No |
| 17828201 | Compositions and Methods for Diagnosing Susceptibility to Autism Spectrum Disorder (ASD), Reducing the Likelihood of Developing ASD, and/or Treating ASD | May 2022 | August 2024 | Allow | 26 | 1 | 2 | Yes | No |
| 17756570 | COMPOSITIONS AND METHODS WITH A PROBIOTIC AND A NUTRIENT AND/OR MINERAL FOR THE PREVENTION OR TREATMENT OF MASTITIS | May 2022 | April 2025 | Abandon | 35 | 0 | 1 | No | No |
| 17755837 | FIBROBLAST-BASED THERAPY FOR TREATMENT AND PREVENTION OF STROKE | May 2022 | June 2025 | Allow | 37 | 0 | 1 | Yes | No |
| 17727934 | CYANOBACTERIAL HOSTS AND METHODS FOR PRODUCING CHEMICALS | April 2022 | January 2024 | Allow | 20 | 1 | 1 | Yes | No |
| 17724386 | METHOD FOR PRODUCING MARINE ALGAE-DERIVED AGAROTRIOSE, AND USE THEREOF AS PREBIOTIC | April 2022 | September 2023 | Allow | 17 | 0 | 1 | Yes | No |
| 17714955 | NOVEL LACTIC ACID BACTERIA AND USE THEREOF | April 2022 | December 2023 | Allow | 21 | 1 | 1 | Yes | No |
| 17762014 | BIFIDOBACTERIUM BREVE 207-1 AND USE THEREOF | March 2022 | June 2023 | Allow | 15 | 1 | 1 | Yes | No |
| 17685568 | SHEET-SHAPED CELL CULTURE PREPARATION DEVICE | March 2022 | April 2025 | Allow | 38 | 1 | 1 | Yes | No |
| 17684323 | COMPOSITION FOR USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER | March 2022 | January 2024 | Allow | 22 | 1 | 2 | Yes | No |
| 17682051 | METHODS FOR INCREASING GROWTH OF BENEFICIAL BACTERIA IN THE GASTROINTESTINAL TRACT | February 2022 | August 2023 | Allow | 18 | 0 | 1 | Yes | No |
| 17671959 | METHOD AND COMPOSITION FOR AMELIORATING DRUG SEEKING BEHAVIOR | February 2022 | December 2023 | Allow | 22 | 1 | 1 | Yes | No |
| 17632211 | METHODS OF IMPROVING PROTEIN PRODUCTIVITY IN FED-BATCH CELL CULTURES | February 2022 | May 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17558043 | Thin Film Cell Encapsulation Devices | December 2021 | January 2024 | Abandon | 25 | 0 | 1 | No | No |
| 17544808 | SOLUBILIZATE WITH CURCUMIN AND OPTIONALLY AT LEAST ONE OTHER ACTIVE SUBSTANCE | December 2021 | November 2023 | Allow | 23 | 1 | 1 | Yes | No |
| 17616591 | METHOD FOR GUT MUCOSA PREPARATION TO ENHANCE MICROBIAL ENGRAFTMENT | December 2021 | August 2023 | Allow | 20 | 0 | 3 | Yes | No |
| 17615419 | HUMAN DISEASED AND NORMAL KIDNEY EPITHELIAL CELL CULTURES AND USES THEREOF | November 2021 | April 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17530114 | COMPOSITIONS AND METHODS FOR TREATMENT OF SKIN DISORDERS | November 2021 | December 2023 | Abandon | 25 | 0 | 1 | No | No |
| 17611782 | PHOTOACTIVATED BLOOD PRODUCTS AND METHODS AND APPARATUS FOR FABRICATION AND USE OF SAME | November 2021 | September 2024 | Allow | 34 | 1 | 1 | Yes | No |
| 17526663 | METHOD FOR MODULATING ENDOTHELIAL GLYCOCALYX STRUCTURE | November 2021 | May 2024 | Allow | 30 | 0 | 3 | Yes | No |
| 17604040 | USE OF EXTRACT FROM RABBIT SKIN INFLAMED BY VACCINIA VIRUS IN TREATING HEMATOPOIETIC SYSTEM DAMAGE | November 2021 | May 2024 | Allow | 31 | 0 | 1 | Yes | No |
| 17454692 | METHOD FOR PURIFYING NEURAL CREST CELLS OR CORNEAL EPITHELIAL CELLS | November 2021 | November 2024 | Allow | 36 | 0 | 1 | Yes | No |
| 17610485 | PLURIPOTENT CELL AGGREGATES AND USE THEREOF | November 2021 | November 2024 | Allow | 36 | 0 | 1 | Yes | No |
| 17521529 | Weight Management Composition | November 2021 | March 2025 | Allow | 40 | 1 | 1 | Yes | No |
| 17609460 | PHARMACEUTICAL COMPOSITION COMPRISING PERIODONTAL TISSUE-DERIVED PLURIPOTENT STEM CELLS FOR PREVENTION OR TREATMENT OF MALE INFERTILITY | November 2021 | November 2024 | Allow | 36 | 0 | 1 | Yes | No |
| 17513901 | METHOD AND A DIETARY COMPOSITION ON REGULATION, TREATMENT, AND PREVENTION OF OBESITY | October 2021 | August 2023 | Allow | 21 | 1 | 1 | Yes | No |
| 17607389 | PHARMACEUTICAL COMPOSITION FOR TREATING SEPSIS OR SYSTEMIC INFLAMMATORY RESPONSE SYNDROME, COMPRISING ISOLATED MITOCHONDRIA AS ACTIVE INGREDIENT | October 2021 | December 2024 | Abandon | 38 | 0 | 2 | No | No |
| 17511228 | GENERATION OF FUNCTIONAL AND PATIENT-SPECIFIC THYMIC TISSUE FROM INDUCED PLURIPOTENT STEM CELLS | October 2021 | April 2025 | Allow | 42 | 0 | 2 | Yes | No |
| 17504668 | PACKAGING FOR WET TISSUE STORAGE | October 2021 | August 2024 | Allow | 34 | 0 | 1 | Yes | No |
| 17503583 | ANIMAL TREATMENT PASTES AND OINTMENTS AND METHODS OF USING SAME | October 2021 | July 2023 | Allow | 21 | 0 | 1 | Yes | No |
| 17604541 | PROCESS FOR OBTAINING BIOLOGICALLY ACTIVE COMPOSITIONS FROM EMU OIL, ANTIINFLAMMATORY AND ANTI-IRRITANT PHARMACEUTICAL COMPOSITION, AND SKIN REGENERATIVE PHARMACEUTICAL COMPOSITION | October 2021 | April 2024 | Allow | 30 | 0 | 1 | Yes | No |
| 17603195 | EARLY LIFE NUTRITION | October 2021 | September 2024 | Allow | 35 | 0 | 1 | Yes | No |
| 17602421 | METHOD FOR PRODUCING BIOLOGICAL TISSUE-LIKE STRUCTURE | October 2021 | November 2024 | Allow | 38 | 1 | 1 | Yes | No |
| 17448684 | EYEDROP APPLICABLE TO LIMBAL STEM CELL DEFICIENCY AND PREPARATION | September 2021 | April 2024 | Allow | 31 | 0 | 1 | Yes | No |
| 17479597 | METHOD OF MAKING STEVIOL GLYCOSIDES | September 2021 | September 2024 | Abandon | 35 | 2 | 0 | No | No |
| 17468485 | SPORE-BASED PROBIOTIC COMPOSITION FOR MODULATION OF DERMAL AND SUB-DERMAL PROPERTIES | September 2021 | June 2023 | Allow | 21 | 0 | 1 | Yes | No |
| 17435437 | INDUCTION METHOD FOR MACROPHAGE, ANTI-INFLAMMATORY MACROPHAGE-INDUCING AGENT, AND PHARMACEUTICAL COMPOSITION | September 2021 | March 2025 | Allow | 42 | 2 | 2 | Yes | No |
| 17434925 | ACOUSTIC EXTRACELLULAR MATRIX HYDROGELS AND THEIR USE | August 2021 | October 2024 | Allow | 38 | 1 | 1 | Yes | No |
| 17434417 | USE OF MESENCHYMAL STEM CELLS IN TREATING IMMUNE-RELATED DISEASES | August 2021 | November 2024 | Allow | 38 | 3 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner KOSSON, ROSANNE.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 25.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner KOSSON, ROSANNE works in Art Unit 1759 and has examined 193 patent applications in our dataset. With an allowance rate of 83.9%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 28 months.
Examiner KOSSON, ROSANNE's allowance rate of 83.9% places them in the 53% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by KOSSON, ROSANNE receive 0.82 office actions before reaching final disposition. This places the examiner in the 8% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by KOSSON, ROSANNE is 28 months. This places the examiner in the 50% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +97.0% benefit to allowance rate for applications examined by KOSSON, ROSANNE. This interview benefit is in the 100% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 33.3% of applications are subsequently allowed. This success rate is in the 65% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 57.7% of cases where such amendments are filed. This entry rate is in the 80% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 3% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 87% percentile among all examiners. Of these withdrawals, 66.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 34.0% are granted (fully or in part). This grant rate is in the 28% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 0.5% of allowed cases (in the 60% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.5% of allowed cases (in the 68% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.